You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
普利製藥(300630.SZ):1批次克拉黴素緩釋片的生產留樣藥品乾燥失重符合規定 不合格的藥品抽樣來自藥品經營環節
格隆匯 09-11 20:55

格隆匯 9 月 11日丨普利製藥(300630.SZ)公佈,2020910日,公司關注到媒體1批次克拉黴素緩釋片不合格190億市值的普利製藥上國藥局黑名單》為題報道,主要內容如下:

910日,國家藥監局公佈20批次藥品不符合規定的通告顯示,A股上市公司海南普利製藥(300630)股份有限公司生產的1批次克拉黴素緩釋片不符合規定不符合規定項目為乾燥失重

公司及時對報道內容進行核實,現就該媒體報道做如下澄清和説明:

202099日,國家藥監局網站發佈《國家藥監局關於20批次藥品不符合規定的通告(2020年第57號)》根據前述通告及其附件,山西省食品藥品檢驗所對來自經營環節藥品進行檢驗發現有一批次公司生產的克拉黴素緩釋片在經營環節因乾燥失重出現不符合規定的情形

公司獲悉後高度重視該批次克拉黴素緩釋片檢驗不合格事宜,積極與多方溝通,瞭解該批次產品符合規定的原因,進行風險隱患自查,經自查公司未發該批次的生產留樣產品不符合規定同時,海南省藥品監督管理局也立即對我公司該批次的生產留樣進行了核查並監督抽樣,經海南省藥品檢驗所檢驗該批次的生產留樣藥品乾燥失重符合規定,不合格的藥品抽樣來自藥品經營環節

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account